NZ623146B2 - Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules - Google Patents
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules Download PDFInfo
- Publication number
- NZ623146B2 NZ623146B2 NZ623146A NZ62314612A NZ623146B2 NZ 623146 B2 NZ623146 B2 NZ 623146B2 NZ 623146 A NZ623146 A NZ 623146A NZ 62314612 A NZ62314612 A NZ 62314612A NZ 623146 B2 NZ623146 B2 NZ 623146B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- mhc
- mouse
- chimeric
- polypeptide
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title claims abstract description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title claims abstract description 5
- 238000011830 transgenic mouse model Methods 0.000 title description 4
- 241000699660 Mus musculus Species 0.000 title description 3
- 241000282414 Homo sapiens Species 0.000 claims abstract description 595
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 211
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 182
- 229920001184 polypeptide Polymers 0.000 claims abstract description 167
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 135
- 239000002773 nucleotide Substances 0.000 claims abstract description 104
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 104
- 241001465754 Metazoa Species 0.000 claims abstract description 45
- 241000283984 Rodentia Species 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 39
- 230000001086 cytosolic effect Effects 0.000 claims description 36
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 30
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims description 30
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 29
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 210000001161 mammalian embryo Anatomy 0.000 claims description 12
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 10
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 10
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 9
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 6
- 230000006303 immediate early viral mRNA transcription Effects 0.000 claims description 6
- 101150062179 II gene Proteins 0.000 claims description 5
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims description 4
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims description 4
- 108700005092 MHC Class II Genes Proteins 0.000 claims description 4
- 108010053491 HLA-DR beta-Chains Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 215
- 210000004027 cell Anatomy 0.000 description 94
- 102000004169 proteins and genes Human genes 0.000 description 51
- 239000000427 antigen Substances 0.000 description 50
- 108091007433 antigens Proteins 0.000 description 50
- 102000036639 antigens Human genes 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 50
- 241000700159 Rattus Species 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 239000013598 vector Substances 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 22
- 108700024394 Exon Proteins 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 108091054438 MHC class II family Proteins 0.000 description 17
- 230000008685 targeting Effects 0.000 description 17
- 102000043131 MHC class II family Human genes 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 14
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 229930193140 Neomycin Natural products 0.000 description 12
- 229960004927 neomycin Drugs 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 9
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 9
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 8
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101150090724 3 gene Proteins 0.000 description 6
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 102400001295 Class-II-associated invariant chain peptide Human genes 0.000 description 5
- 101800001887 Class-II-associated invariant chain peptide Proteins 0.000 description 5
- 230000002121 endocytic effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 241000699729 Muridae Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 108091008109 Pseudogenes Proteins 0.000 description 4
- 102000057361 Pseudogenes Human genes 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 210000005220 cytoplasmic tail Anatomy 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000011714 129 mouse Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 108010033222 HLA-DRB1*04 antigen Proteins 0.000 description 3
- 101000968028 Homo sapiens HLA class II histocompatibility antigen, DRB1 beta chain Proteins 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010028930 invariant chain Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 101000968009 Homo sapiens HLA class II histocompatibility antigen, DR alpha chain Proteins 0.000 description 2
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000398750 Muroidea Species 0.000 description 2
- 101100123457 Mus musculus H2-Ab1 gene Proteins 0.000 description 2
- 101100450101 Mus musculus H2-Ea gene Proteins 0.000 description 2
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008138 Composite lymphoma Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 101150018610 HLA-DRB1 gene Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101000738546 Homo sapiens Protein PTHB1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001046461 Lophiomys imhausi Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101150113332 O4 gene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BUDBHJPMAKXMLD-UHFFFAOYSA-N ethyl 6-methyl-2-phenylquinoline-4-carboxylate Chemical compound N=1C2=CC=C(C)C=C2C(C(=O)OCC)=CC=1C1=CC=CC=C1 BUDBHJPMAKXMLD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000051324 human BBS9 Human genes 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 230000009403 human autoimmunity Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 244000000011 human parasite Species 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 108010083551 iturelix Proteins 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
Abstract
Disclosed is a non-human animal comprising at an endogenous Major Histocompatibility Complex II (MHC II) ? gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II ? polypeptide and/or comprising at an endogenous MHC II ? gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II ? polypeptide, wherein a human portion of the chimeric human/non-human MHC II ? polypeptide comprises a human MHC II ?2 extracellular domain, and/or a human portion of the chimeric human/non-human MHC II ? polypeptide comprises human MHC II ?2 domains, and wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal. non-human MHC II ? polypeptide, wherein a human portion of the chimeric human/non-human MHC II ? polypeptide comprises a human MHC II ?2 extracellular domain, and/or a human portion of the chimeric human/non-human MHC II ? polypeptide comprises human MHC II ?2 domains, and wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal.
Description
TRANSGENIC MICE SING CHIMERIC MAJOR HISTOCOMPATIBILITY X (MHC)
CLASS II MOLECULES
CROSS-REFERENCE TO RELATED APPLICATION
This application claims benefit of priority to US. Provisional Application
No. 61/552,584, filed October 28, 2011, which is incorporated by reference herein in its
entirety.
FIELD OF THE INVENTION
Present invention relates to a non-human animal, e.g., a rodent (e.g., a mouse or
a rat) that is genetically engineered to s a zed Major Histocompatibiiity
Complex (MHC) class II protein, as well as embryos, tissues, and cells expressing the same.
The invention r relates to methods for making a genetically modified non—human
animal that ses a humanized MHC II protein. Also provided are methods for using
non-human s, cells, and tissues that express a humanized MHC class II protein for
identifying peptides that activate lymphocytes and engage T cells, and for developing human
es and other therapeutics.
BACKGROUND OF THE INVENTION
In the adaptive immune response, foreign antigens are recognized by receptor
molecules on B cytes (e.g., immunoglobulins) and T cytes (e.g., T cell
receptor or TCR). These foreign antigens are presented on the surface of cells as peptide
fragments by specialized proteins, generically referred to as major histocompatibility
complex (MHC) molecules. MHC molecules are encoded by multiple loci that are found as a
linked cluster of genes that spans about 4 Mb. In mice, the MHC genes are found on
chromosome 17, and for historical reasons are referred to as the histocompatibility 2 (H-2)
genes. In humans, the genes are found on chromosome 6 and are called human leukocyte
n (HLA) genes. The loci in mice and humans are nic; they include three highly
polymorphic classes of MHC genes (class l, ll and Ill) that exhibit similar organization in
human and murine genomes (see and respectively).
MHC loci exhibit the highest polymorphism in the genome; some genes are
represented by >300 alleles (e.g., human HLA-DRB and human HLA—B). All class I and ll
MHC genes can present peptide fragments, but each gene ses a protein with different
g characteristics, reflecting polymorphisms and allelic variants. Any given individual
has a unique range of peptide fragments that can be presented on the cell e to B and
T cells in the course of an immune response.
Both humans and mice have class ll MHC genes (see Fle. 2 and 3). In
humans, the classical MHC ll genes are termed HLA-DP, , and HLA-DR, whereas in
mice they are H-2A and H-2E (often iated as l-A and l—E, respectively). Additional
proteins encoded by genes in the MHC ll locus, HLA—DM and HLA-DO in humans, and H-2M
and H-20 in mice, are not found on the cell surface, but reside in the endocytic compartment
and ensure proper loading of MHC ll molecules with peptides. Class ll molecules consist of
two polypeptide chains: on chain and [3 chain. The extracellular portion of the on chain
contains two extracellular domains, at and (x2; and the extracellular portion of the [3 chain
also contains two extracellular domains, [31 and [32 (see . The on and the [3 chains are
non-covalently associated with each other.
MHC class ll molecules are expressed on antigen—presenting cells (APCs), e.g.,
B cells, macrophages, dendritic cells, endothelial cells during a course of inflammation, etc.
MHC ll molecules sed on the surface of APCs typically present antigens ted in
intracellular vesicles to CD4+ T cells. In order to participate in CD4+ T cell engagement, the
MHC class ll complex with the antigen of interest must be sufficiently stable to survive long
enough to engage a CD4+ T cell. When a CD4+ T helper cell is engaged by a foreign
e/MHC |l complex on the surface of APC, the T cell is activated to release cytokines
that assist in immune response to the r.
Not all antigens will provoke T cell activation due to tolerance mechanisms.
r, in some diseases (e.g., cancer, autoimmune diseases) peptides derived from self-
proteins become the target of the cellular component of the immune system, which s in
ction of cells presenting such peptides. There has been significant advancement in
recognizing antigens that are clinically significant (e.g., antigens associated with various
types of cancer). However, in order to improve identification and selection of peptides that
will provoke a suitable response in a human T cell, in particular for peptides of clinically
significant antigens, there remains a need for in vivo and in vitro systems that mimic aspects
of human immune system. Thus, there is a need for biological systems (e.g., cally
modified non-human animals and cells) that can display components of a human immune
system.
SUMMARY OF THE INVENTION
A biological system for generating or identifying peptides that associate with
human MHC class II ns and chimeras thereof, and bind to CD4+ T cells, is provided.
Non-human animals comprising non-human cells that s humanized les that
function in the cellular immune response are provided. zed rodent loci that encode
humanized MHC II proteins are also provided. Humanized rodent cells that express
humanized MHC molecules are also provided. In vivo and in vitro systems are provided that
comprise humanized rodent cells, wherein the rodent cells express one or more humanized
immune system molecules.
Provided herein is a non-human animal, e.g., a rodent (e.g., a mouse or a rat)
comprising in its genome a nucleotide sequence ng a zed MHC II x,
wherein a human portion of the zed MHC II complex comprises an extracellular
domain of a human MHC II complex, e.g., a zed MHC II extracellular domain and a
humanized MHC II extracellular domain.
In one aspect, provided herein is a non-human animal comprising at an
endogenous Major Histocompatibility Complex II (MHC II) gene locus a nucleotide
sequence encoding a chimeric human/non-human MHC II polypeptide and/or comprising at
an endogenous MHC II β gene locus a nucleotide sequence encoding a ic human/nonhuman
MHC II β ptide,
wherein a human portion of the chimeric human/non-human MHC II polypeptide
comprises a human MHC II 2 extracellular domain, and/or a human portion of the chimeric
human/non-human MHC II β polypeptide comprises human MHC II β2 domains, and
wherein the animal expresses a functional MHC II complex on a surface of a cell of
the animal.
] In a further aspect, provided herein is a method of modifying an MHC II locus of a
mouse to express a ic human/mouse MHC II complex comprising replacing at the
endogenous mouse MHC II α locus a nucleotide sequence encoding a mouse MHC II α
protein with a first nucleotide sequence encoding a chimeric human/mouse MHC II α protein
and/or at the endogenous mouse MHC II β locus a nucleotide sequence encoding a mouse
MHC II β protein with a second nucleotide sequence encoding a chimeric human/mouse MHC
II β protein, wherein the chimeric human/mouse MHC II α protein comprises an α2 domain of
a human MHC II polypeptide and transmembrane and cytoplasmic domains of a mouse
MHC II polypeptide and the chimeric human/mouse MHC II β protein ses a β2
domain of a human MHC II β polypeptide and transmembrane and cytoplasmic domains of a
mouse MHC II β polypeptide.
[0010b] In a further aspect, ed herein is a non-human animal comprising at an
endogenous MHC II gene locus a nucleotide sequence encoding a chimeric human/nonhuman
MHC II polypeptide. In one embodiment, a human portion of such chimeric
human/non-human MHC II polypeptide comprises a human MHC II extracellular domain.
In one embodiment, the non-human animal expresses a onal MHC II complex on a
surface of a cell of the animal. In one embodiment, the human MHC II extracellular domain
in the animal comprises human MHC II 1 and 2 domains; in one embodiment, a nonhuman
portion of the ic human/non-human MHC II polypeptide comprises
transmembrane and cytoplasmic domains of an endogenous man MHC II
polypeptide. In one embodiment, the nucleotide ce encoding a chimeric nonhuman
MHC II polypeptide is expressed under regulatory control of endogenous nonhuman
MHC II promoter and regulatory elements. In one embodiment, the human portion
of the chimeric polypeptide is derived from a human HLA class II protein selected from the
group consisting of HLA-DR, HLA-DQ, and HLA-DP, e.g., the human portion is derived from
HLA-DR4 protein. The non-human animal may be a rodent, e.g., a mouse. In one ,
the non-human animal comprising at an nous MHC II gene locus a nucleotide
sequence encoding a chimeric human/non-human MHC II polypeptide further comprises
at an endogenous MHC II [5 gene locus a tide sequence encoding a chimeric
human/non-human MHC II [3 polypeptide. Also provided herein is a method of making a
genetically modified non—human animal comprising at an endogenous MHC II a gene locus
a nucleotide sequence encoding a chimeric human/non-human MHC II on polypeptide. Such
method may comprise replacing at an endogenous MHC II on gene locus a nucleotide
sequence encoding an endogenous non-human MHC II a ptide with a nucleotide
sequence encoding a chimeric human/non-human MHC II on polypeptide.
Also provided herein is a non—human animal comprising at an endogenous MHC
II (3 gene locus a nucleotide ce encoding a chimeric human/non-human MHC II [3
ptide. In one embodiment, a human portion of such chimeric human/non-human
MHC II [3 polypeptide comprises a human MHC II p extracellular domain. In one
embodiment, the non—human animal ses a functional MHC II complex on a surface of
a cell of the animal. In one embodiment, the human MHC ll B extracellular domain in the
animal comprises human MHC || [31 and [52 domains; in one embodiment, a non-human
portion of the chimeric human/non-human MHC II [3 polypeptide ses transmembrane
and cytoplasmic s of an endogenous non-human MHC II p polypeptide. In one
embodiment, the nucleotide sequence encoding a chimeric human/non-human MHC II [3
polypeptide is expressed under regulatory control of endogenous man MHC II [3
promoter and regulatory elements. In one embodiment, the human portion of the ic
polypeptide is derived from a human HLA class II n selected from the group consisting
of HLA-DR, , and HLA-DP, e.g., the human n is derived from HLA-DR4
protein. The non-human animal may be a rodent, e.g., a mouse. In one aspect, the non—
human animal comprising at an endogenous MHC II [3 gene locus a tide sequence
encoding a chimeric human/non-human MHC II [3 polypeptide further comprises at an
endogenous MHC II on gene locus a nucleotide sequence encoding a chimeric human/non-
human MHC II a ptide. Also ed herein is a method of making a genetically
modified non-human animal comprising at an endogenous MHC II [3 gene locus a nucleotide
sequence encoding a chimeric human/non-human MHC II [3 polypeptide. Such method may
comprise replacing at an endogenous MHC II B gene locus a tide sequence encoding
an endogenous non—human MHC ll {3 polypeptide with a nucleotide sequence encoding a
chimeric human/non-human MHC II [5 polypeptide.
In one aspect, a non-human animal is provided sing at an endogenous
MHC II gene locus a first nucleotide sequence encoding a chimeric human/non-human MHC
II 0t polypeptide and a second nucleotide sequence encoding a chimeric human/non—human
MHC II [3 polypeptide, wherein a human portion of the ic human/non-human MHC II or
polypeptide comprises a human MHC II or extracellular domain and a human portion of the
chimeric human/non-human MHC II [3 polypeptide comprises a human MHC II B extracellular
domain. In one embodiment, the chimeric human/non-human MHC II or and B ptides
form a functional chimeric MHC II complex (e.g., non-human MHC II complex) on a
surface of a cell. In one embodiment, the human MHC II or extracellular domain comprises
human a1 and a2 domains of human MHC II. In one embodiment, the human MHC II B
extracellular domain comprises human [31 and [32 domains of human MHC II. In various
aspects, the first nucleotide sequence is sed under regulatory control of endogenous
non-human MHC II or promoter and regulatory elements. In s aspects, the second
nucleotide sequence is expressed under regulatory control of endogenous non-human MHC
II [5 promoter and regulatory elements. In some embodiments, a non—human portion of the
chimeric human/non-human MHC II or polypeptide ses transmembrane and
cytoplasmic domains of an endogenous non-human MHC II or ptide. In some
embodiments, a non-human portion of the chimeric human/non-human MHC II [5 polypeptide
comprises embrane and asmic domains of an endogenous non-human MHC II
[5 polypeptide.
In various embodiments, the non-human animal is a , and the human
portions of the chimeric human/rodent MHC II or and fi polypeptides comprise human
sequences derived from HLA class M protein ed from the group consisting of HLA-DR,
HLA-DQ, and HLA-DP. In some embodiments of the invention, the human portions of the
chimeric human/rodent MHC II or and [3 sequences are derived from a human 4
sequence; thus, the nucleotide sequence encoding the MHC II or extracellular domain is
derived from a sequence of an HLA-DRa*01 gene, and the nucleotide ce encoding
the MHC II [3 extracellular domain is derived from a sequence encoding an HLA-DR[31*O4
gene.
In various embodiments of the invention, the first and the second nucleotide
sequences are located on the same chromosome. In some aspects, the animal comprises
two copies of the MHC II locus containing the first and the second nucleotide sequences,
while in other aspects, the animal comprises one copy of the MHC II locus containing the
first and the second nucleotide sequences. Thus, the animal may be homozygous or
zygous for the MHC II locus containing the first and the second tide sequences.
In some aspects, the chimeric MHC II or polypeptide and/or the chimeric MHC II {5
polypeptide is operably linked to a non-human leader sequence.
WO 63340
In one aspect, the cally engineered non-human animal is a rodent. In one
embodiment, the rodent is selected from the group consisting of a mouse and a rat. Thus, in
some embodiments, non-human sequences of the chimeric MHC ll or and [3 genes are
derived from nucleotide sequences encoding mouse MHC ll protein, e.g., a mouse H-2E
n. in one embodiment, the rodent (e.g., the mouse or the rat) of the invention does not
express functional endogenous MHC II polypeptides from their endogenous loci. In one
embodiment, wherein the rodent is a mouse, the mouse does not express functional
endogenous H-2E and H-2A polypeptides from their endogenous loci.
Thus, in some embodiments, a mouse is provided comprising at an endogenous
mouse MHC ll locus a first nucleotide sequence encoding a chimeric human/mouse MHC II
0L polypeptide and a second nucleotide ce encoding a chimeric human/mouse MHC ll
[3 polypeptide, n a human portion of the chimeric MHC II or polypeptide comprises an
extracellular domain derived from an on polypeptide of a human HLA-DR4 protein and a
human portion of the ic human/mouse MHC ll 6 polypeptide comprises an
extracellular domain derived from a B polypeptide of a human HLA-DR4 protein, wherein a
mouse portion of the chimeric MHC ll or ptide comprises transmembrane and
asmic domains of a mouse H-2E a chain and a mouse portion of the chimeric MHC ll
[3 polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E [3
chain, and wherein the mouse expresses a functional chimeric HLA-DR4/H-2E MHC ll
complex. In some aspects, the extracellular domain of the ic MHC ll 0L polypeptide
comprises human 0:1 and a2 domains; in some aspects, the extracellular domain of the
ic MHC II [3 polypeptide ses human B1 and {52 domains. In some
embodiments, the first nucleotide sequence is sed under regulatory l of
endogenous mouse MHC ll 0t er and regulatory elements, and the second nucleotide
sequence is expressed under regulatory control of endogenous mouse MHC II [3 promoter
and regulatory elements. In various ments, the mouse does not express functional
endogenous MHC ll polypeptides, e.g., H-2E and H-2A polypeptides, from their endogenous
loci. In some aspects, the mouse comprises two copies of the MHC II locus containing the
first and the second nucleotide sequences, while in other aspects, the mouse comprises one
copy of the MHC II locus containing the first and the second nucleotide sequences.
Methods of making genetically engineered non-human animals (e.g., rodents,
e.g., mice or rats) as described herein are also provided. In various embodiments, non-
human animals (e.g., rodents, e.g., mice or rats) of the invention are made by replacing
endogenous MHC II sequences with nucleotide sequences encoding chimeric human/non-
human (e.g., human/mouse) MHC II or and [3 ptides. In one embodiment, the
invention provides a method of ing an MHC II locus of a rodent (e.g., a mouse or a
rat) to s a chimeric rodent MHC II complex comprising replacing at the
endogenous mouse MHC II locus a nucleotide sequence ng a rodent MHC II complex
with a nucleotide sequence encoding a chimeric human/rodent MHC II complex. In one
aspect of the method, the nucleotide sequence encoding the chimeric human/rodent MHC II
complex comprises a first nucleotide sequence encoding an extracellular domain of a human
MHC II at chain and transmembrane and cytoplasmic domains of a rodent MHC II 0t chain
and a second nucleotide sequence encoding an extracellular domain of a human MHC II [3
chain and transmembrane and cytoplasmic domains of a rodent MHC II B chain. In some
aspects, a rodent portion of the chimeric MHC II complex is derived from a mouse H-2E
n, and a human portion is derived from a human HLA—DR4 n. In some
embodiments, the replacement of the endogenous MHC II loci described herein is made in a
single ES cell, and the single ES cell is introduced into a rodent (e.g., mouse or rat) embryo
to make a genetically modified rodent (e.g., mouse or rat).
Also provided herein are cells, e.g., isolated antigen—presenting cells, derived
from the non-human s (e.g., rodents, e.g., mice or rats) described herein. Tissues
and embryos derived from the non—human animals described herein are also provided.
Any of the embodiments and aspects described herein can be used in
conjunction with one another, unless othenNise indicated or nt from the context.
Other embodiments will become nt to those skilled in the art from a review of the
ensuing detailed description. The following detailed description includes exemplary
representations of various embodiments of the invention, which are not restrictive of the
invention as claimed. The accompanying figures constitute a part of this specification and,
together with the description, serve only to illustrate embodiments and not to limit the
invenfion.
BRIEF DESCRIPTION OF THE DRAWINGS
is a schematic drawing of the MHC II class molecule expressed on the
surface of an antigen presenting cell (APC), containing four domains: (11, a2, [31, and $2.
The gray circle ents a peptide bound in the peptide-binding cleft.
is a tic representation (not to scale) of the relative genomic
structure of the human HLA, showing class I, II and Ill genes.
is a schematic representation (not to scale) of the relative genomic
ure of the mouse MHC, showing class I, II and Ill genes.
(A-D) is a schematic ration (not to scale) of the strategy for generating
a targeting vector comprising humanized l-E [3 and l-E 0L (i.e., H-2EB/HLA—DRfi1*O4 and H-
2Ea/HLA—DRa*O1 chimera, respectively). In , the final zed MHC II sequence
from is ligated between l and I-Ceul restriction sites of the final construct from
, to generate a construct comprising humanized MHC II and exon 1 of I-Eoc from
. Pg=pseudogene; BHR= bacterial homologous recombination;
CM=chloramphenicol; spec=spectinomycin; hyg=hygromycin; neo=neomycin;
EP=electroporation. Triangles represent exons, filled les represent mouse exons from
057BL/6 mouse (with the exception of hashed triangles, which represent exon 1 of l-Ea
from BALB/c mouse) and open triangles represent human exons.
shows a schematic illustration, not to scale, of MHC class II l—E and l-A
genes, showing knockout of the mouse locus using a ycin cassette, ed by
introduction of a vector comprising a humanized I-E [3 and l-E or (i.e., H-2EB/HLA—DR61*04
and /HLA-DRor*01 chimera, respectively). Open triangles represent human exons;
filled triangles represent mouse exons. Probes used for genotyping are encircled.
shows a schematic illustration, not to scale, of Ore—mediated removal of
the neomycin cassette of Open triangles represent human exons; filled triangles
represent mouse exons. Top two strands represent MHC II loci in humanized MHC II
heterozygous mouse ing a neomycin selection cassette, and bottom two strands
represent MHC II loci in humanized MHC II heterozygous mouse with neomycin cassette
removed.
’ shows a schematic ative ration, not to scale, of mouse and
human class II loci. Class II genes are represented by boxes, and empty boxes represent
pseudogenes. Relative sizes (kb) of various nucleic acid fragments are included.
at left panel, is a schematic illustration (not to scale) of humanization
strategy for the MHC II or chain; in particular, the figure shows a replacement of a1 and 012
domains, encoded by exons 2 and 3 of MHC II or gene, while retaining mouse
transmembrane and cytoplasmic tail sequences. In the humanized locus, the MHC II a
leader sequence is derived from the mouse BALB/c strain. The right panel illustrates
humanization of the MHC II [5 chain; in particular, the figure shows a replacement of {31 and
[32 domains, encoded by exons 2 and 3 of MHC II [3 gene, while retaining the mouse leader
and mouse transmembrane and asmic tail sequences. Top row are all human
sequences; middle row are all mouse sequences; bottom row are all humanized sequences,
with exons 2 and 3 derived from human HLA-DR genes.
shows FACS analysis with anti-HLA-DR antibody of B cells from a mouse
heterozygous for a chimeric HLA-DR4 (neo cassette d) in the presence (1681 HET +
po|y(l:C) or absence (1681 HET) of poly(I:C), and a wild-type mouse (WT mouse).
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The present invention provides genetically modified non-human animals (e.g.,
mice, rats, rabbits, etc.) that express human or humanized MHC ll polypeptide; embryos,
cells, and tissues comprising the same; s of making the same; as well as methods of
using the same. Unless defined ise, all terms and phrases used herein include the
meanings that the terms and phrases have attained in the art, unless the contrary is clearly
indicated or clearly apparent from the context in which the term or phrase is used.
The term "conservative,” when used to describe a vative amino acid
substitution, includes substitution of an amino acid e by another amino acid e
having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity).
Conservative amino acid substitutions may be achieved by modifying a nucleotide sequence
so as to introduce a nucleotide change that will encode the conservative substitution. In
general, a conservative amino acid substitution will not substantially change the functional
properties of interest of a protein, for example, the ability of MHC II to t a peptide of
interest. Examples of groups of amino acids that have side chains with similar chemical
properties include aliphatic side chains such as glycine, alanine, , leucine, and
isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing
side chains such as asparagine and glutamine; aromatic side chains such as alanine,
ne, and tryptophan; basic side chains such as , ne, and histidine; acidic side
chains such as aspartic acid and glutamic acid; and, sulfur-containing side chains such as
cysteine and methionine. Conservative amino acids substitution groups include, for example,
valine/leucine/isoleucine, phenylalanine/tyrosine, lysine/arginine, alanine/valine,
glutamate/aspartate, and asparagine/glutamine. In some embodiments, a conservative
amino acid tution can be a substitution of any native residue in a n with alanine,
as used in, for example, alanine scanning mutagenesis. In some embodiments, a
conservative substitution is made that has a positive value in the PAM250 log-likelihood
matrix disclosed in Gonnet et al. ((1992) tive ng of the Entire Protein
Sequence Database, Science 256:1443—45), hereby incorporated by reference. In some
embodiments, the substitution is a moderately conservative substitution wherein the
substitution has a nonnegative value in the PAM250 log-likelihood matrix.
2012/062029
Thus, also encompassed by the invention is a genetically modified non—human
animal whose genome comprises a nucleotide sequence encoding a human or humanized
MHC II polypeptide, wherein the polypeptide comprises conservative amino acid
substitutions in the amino acid sequence described herein.
One skilled in the art would understand that in addition to the nucleic acid
residues encoding a human or humanized MHC ll ptide bed herein, due to the
degeneracy of the c code, other c acids may encode the polypeptide of the
invention. Therefore, in addition to a genetically modified non-human animal that ses
in its genome a nucleotide sequence encoding MHC II polypeptide with conservative amino
acid substitutions, a non-human animal whose genome comprises a nucleotide ce
that s from that described herein due to the degeneracy of the genetic code is also
The term “identity” when used in connection with ce includes identity as
determined by a number of different algorithms known in the art that can be used to
measure nucleotide and/or amino acid sequence identity. In some embodiments described
herein, identities are ined using a ClustalW v. 1.83 (slow) alignment employing an
open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix
(MacVectorTM 10.0.2, MacVector Inc., 2008). The length of the sequences compared with
respect to identity of sequences will depend upon the particular sequences. In various
embodiments, identity is determined by comparing the sequence of a mature protein from its
inal to its C-terminal. In various embodiments when comparing a chimeric
human/non-human sequence to a human sequence, the human portion of the chimeric
human/non—human sequence (but not the man portion) is used in making a
comparison for the purpose of ascertaining a level of ty between a human sequence
and a human portion of a chimeric human/non-human ce (e.g., comparing a human
ectodomain of a chimeric human/mouse protein to a human ectodomain of a human
protein).
The terms ogy” or “homologous” in reference to sequences, e.g.,
nucleotide or amino acid sequences, means two sequences which, upon optimal alignment
and comparison, are identical in at least about 75% of nucleotides or amino acids, at least
about 80% of nucleotides or amino acids, at least about 90-95% nucleotides or amino acids,
e.g., greater than 97% nucleotides or amino acids. One skilled in the art would understand
that, for optimal gene targeting, the targeting construct should contain arms homologous to
endogenous DNA sequences (i.e., “homology arms”); thus, homologous recombination can
occur between the targeting construct and the targeted endogenous sequence.
The term bly linked" refers to a juxtaposition n the components so
described are in a relationship permitting them to function in their intended manner. As
such, a nucleic acid sequence encoding a protein may be operably linked to regulatory
sequences (e.g., promoter, enhancer, silencer sequence, etc.) so as to retain proper
transcriptional regulation. In addition, various portions of the chimeric or humanized protein
of the invention may be operably linked to retain proper folding, processing, targeting,
expression, and other functional properties of the protein in the cell. Unless stated
otherwise, various domains of the chimeric or humanized protein of the invention are
operably linked to each other.
The terms “MHC ll complex,” “MHC ll protein,” or the like, as used herein, e
the complex between an MHC II a polypeptide and an MHC ll [3 polypeptide. The term
“MHC II 0L ptide” or “MHC II [3 polypeptide” (or the like), as used herein, includes the
MHC I OL polypeptide alone or MHC ll [3 polypeptide alone, respectively. rly, the terms
“HLA—DR4 complex”, “HLA—DR4 n,” “H—2E x,” “H-2E” protein,” or the like, refer
to complex between on and [3 polypeptides. Typically, the terms “human MHC” and ”HLA”
are used interchangeably.
The term “replacement” in nce to gene replacement refers to g
exogenous genetic material at an endogenous genetic locus, thereby replacing all or a
portion of the endogenous gene with an orthologous or homologous nucleic acid sequence.
As demonstrated in the Examples below, nucleic acid sequence of endogenous MHC ll
locus was replaced by a tide sequence comprising sequences encoding portions of
human MHC ll 0L and [3 polypeptides; specifically, ng the extracellular portions of the
MHC ll 0t and [3 polypeptides.
“Functional” as used herein, e.g., in nce to a functional polypeptide, refers
to a polypeptide that retains at least one biological activity normally associated with the
native protein. For example, in some embodiments of the invention, a replacement at an
endogenous locus (e.g., replacement at an endogenous non—human MHC II locus) results in
a locus that fails to express a functional endogenous polypeptide.
Genetically ed MHC ll Animals
In various s, the invention generally provides genetically modified non-
human animals that comprise in their genome a nucleotide sequence encoding a human or
humanized MHC ll x; thus, the animals express a human or humanized MHC II
complex (e.g., MHC II 0t and [3 polypeptides).
MHC genes are categorized into three classes: class I, class II, and class III, all
of which are encoded either on human chromosome 6 or mouse chromosome 17. A
schematic of the relative organization of the human and mouse MHC classes is presented in
FIGs. 2 and 3, respectively. The majority of MHC genes are polymorphic, in fact they are
the most polymorphic genes of the mouse and human genomes. MHC polymorphisms are
ed to be important in providing evolutionary advantage; changes in sequence can
result in differences in peptide binding that allow for better n presentation. One
exception is the human a chain and its mouse homolog, Ea (i.e., H-2Ea), which are
monomorphic.
MHC class II complex comprises two valently associated domains: an on
chain and a 0 chain, also referred herein as an 0L ptide and a [3 polypeptide (.
The protein spans the plasma membrane; thus it contains an extracellular domain, a
transmembrane domain, and a cytoplasmic domain. The extracellular n of the a chain
includes (11 and (12 domains, and the extracellular portion of the [3 chain includes [31 and [32
domains. The (11 and [31 domains form a peptide—binding cleft on the cell surface. Due to
the three-dimensional confirmation of the peptide-binding cleft of the MHC II complex, there
is theoretically no upper limit on the length of the bound antigen, but typically peptides
presented by MHC II are between 13 and 17 amino acids in length.
In addition to its interaction with the antigenic peptides, the peptide-binding cleft
of the MHC II molecule interacts with invariant chain (Ii) during the ses of MHC II
complex formation and peptide acquisition. The (x/B MHC II dimers assemble in the
asmic lum and associate with Ii chain, which is responsible for control of peptide
binding and targeting of the MHC II into endocytic pathway. In the endosome, Ii undergoes
lysis, and a small fragment of Ii, Class II-associated invariant chain peptide (CLIP),
remains at the peptide-binding cleft. In the endosome, under control of HLA-DM (in
humans), CLIP is exchanged for antigenic peptides.
MHC II interacts with T cell co—receptor CD4 at the hydrophobic crevice at the
junction between a2 and [32 domains. Wang and Reinherz (2002) Structural Basis of T Cell
Recognition of Peptides Bound to MHC Molecules, lar Immunology, 38:1039-49.
When CD4 and T cell receptor bind the same MHC II moIecule complexed with a peptide,
the sensitivity of a T cell to antigen is increased, and it es 100-fold Iess antigen for
activation. See, Janeway’s Immunobiology, 7th Ed., Murphy et al. eds., Garland Science,
2008, incorporated herein by reference.
Numerous functions have been proposed for transmembrane and asmic
domains of MHC II. In the case of asmic domain, it has been shown to be important
for intracellular signaling, cking to the plasma membrane, and tely, antigen
presentation. For example, it was shown that T cell hybridomas respond poorly to antigen-
presenting cells (APCs) transfected with MHC II [:3 chains truncated at the cytoplasmic
domain, and induction of B cell differentiation is hampered. See, e.g., Smiley et al. (1996)
Truncation of the class II B-chain cytoplasmic domain influences the level of class II/invariant
chain-derived peptide complexes, Proc. Natl. Acad. Sci. USA, 93:241-44. Truncation of
Class II molecules seems to impair CAMP production. It has been postulated that deletion of
the cytoplasmic tail of MHC II affects intracellular trafficking, thus preventing the complex
from coming across relevant antigens in the endocytic pathway. Smiley et al. (supra)
demonstrated that truncation of class II molecules at the cytoplasmic domain reduces the
number of CLIP/class II complexes, postulating that this affects the ability of CLIP to
effectively regulate n presentation.
It has been hypothesized that, since MHC II clustering is important for T cell
receptor (TCR) ring, if MHC II molecules truncated at the asmic domain were
prevented from binding cytoskeleton and thus aggregating, antigen presentation to T cells
would be affected. Ostrand—Rosenberg et al. (1991) Abrogation of Tumorigenicity by MHC
Class II Antigen Expression Requires the Cytoplasmic Domain of the Class II Molecule, J.
Immunol. 147:2419-22. In fact, it was ly shown that HLA—DR truncated at the
cytoplasmic domain failed to associate with the cytoskeleton following oligomerization. El
Fakhy et al. (2004) Delineation of the HLA—DR Region and the Residues Involved in the
ation with the Cytoskeleton, J. Biol. Chem. 279:18472-80. Importantly, actin
eleton is a site of localized signal transduction activity, which can effect antigen
presentation. In on to ation with cytoskeleton, recent studies have also shown
that up to 20% of all HLA-DR molecules constitutively reside in the lipid rafts of APCs, which
are microdomains rich in cholesterol and glycosphingolipids, and that such localization is
important for antigen presentation, immune synapse formation, and MHC II-mediated
signaling. See, e.g., Dolan et al. (2004) Invariant Chain and the MHC II Cytoplasmic
Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-
Based Vaccines, J. Immunol. 7~14. Dolan et al. ted that truncation of
cytoplasmic domain of MHC II reduces constitutive localization of MHC II to lipid rafts.
In addition, the asmic domain of MHC II, in particular the [3 chain, ns
a leucine residue that is subject to ubiquitination by ubiquitin ligase, membrane-associated
RING-CH | (MARCH I), which controls endocytic trafficking, alization, and degradation
of MHC II; and it has been shown that MARCH-mediated ubiquitination ceases upon
dendritic cell maturation resulting in increased levels of MHC II at the plasma membrane.
Shin et al. (2006) Surface expression of MHC class II in tic cells is controlled by
regulated ubiquitination, Nature 444:115-18; De Gassart et al. (2008) MHC class ll
stabilization at the surface of human dendritic cells is the result of maturation-dependent
MARCH l down-regulation, Proc. Natl. Acad. Sci. USA 105:3491—96.
Transmembrane domains of 0c and [5 chains of MHC ll ct with each other
and this interaction is important for proper assembly of class ll MHC complex. Cosson and
Bonifacino (1992) Role of Transmembrane Domain interactions in the Assembly of Class ll
MHC Molecules, Nature 258:659-62. In fact, MHC ll molecules in which the transmembrane
domains of the 0L and [3 chains were ed by the OL chain of lL-2 receptor were retained
in the ER and were barely detectable at the cell surface. Id. Through mutagenesis studies,
conserved Gly residues at the on and [5 transmembrane domains were found to be
responsible for MHC ll assembly at the cell surface. Id. Thus, both transmembrane and
cytoplasmic domains are crucial for the proper function of the MHC ll complex.
In various embodiments, the invention provides a cally modified non-
human animal (e.g., mouse, rat, rabbit, etc.) that comprises in its genome a nucleotide
sequence encoding a human or humanized MHC ll complex, e.g., a human or humanized
MHC ll oz and/or B polypeptide(s). The non—human animal may comprise in its genome a
nucleotide sequence that s an MHC II complex that is partially human and lly
man, e.g., a non-human animal that expresses a chimeric human/non—human MHC ll
complex (e.g., a non-human animal that ses chimeric human/non-human MHC ll cc
and B ptides). in one aspect, the non-human animal only ses the human or
humanized MHC II complex, e.g., a chimeric human/non-human MHC ll complex, and does
not express an endogenous non-human MHC II complex from an endogenous MHC ll locus.
in some embodiments, the animal is incapable of expressing any endogenous non—human
MHC ll complex from an endogenous MHC ll locus, but only ses the human or
humanized MHC ll complex. In various embodiments, the genetically modified non-human
animal (e.g., mouse, rat, rabbit, etc.) ses in its germline a nucleotide sequence
encoding a human or humanized MHC l| complex, e.g., a human or humanized MHC ll 0t
and/or [3 polypeptide(s).
in one aspect, a chimeric human/non-human MHC ll complex is provided. in one
ment, the chimeric human/non-human MHC ll complex comprises a chimeric
human/non—human MHC II a polypeptide and a ic human/non-human MHC II [3
polypeptide. in one aspect, a human portion of the chimeric MHC ll a polypeptide and/or a
human portion of the ic MHC ll [3 polypeptide comprises a peptide-binding domain of
a human MHC II 0t polypeptide and/or human MHC ll [3 polypeptide, respectively. In one
aspect, a human portion of the chimeric MHC II (1 and/or [5 polypeptide comprises an
extracellular domain of a human MHC II on and/or [3 polypeptide, tively. In one
embodiment, a human portion of the chimeric MHC ll 0L polypeptide comprises a1 domain of
a human MHC II on polypeptide; in another embodiment, a human portion of the chimeric
MHC ll 0L polypeptide comprises a1 and a2 domains of a human MHC II 0t ptide. In
an additional embodiment, a human portion of the chimeric MHC ll (5 polypeptide comprises
[31 domain of a human MHC ll {3 polypeptide; in r embodiment, a human portion of the
chimeric MHC ll [3 polypeptide comprises [31 and [32 domains of a human MHC ll [3
polypeptide.
The human portion of the MHC II on and [3 polypeptides described herein may be
encoded by any of HLA-DP, -DQ, and —DR loci. A list of commonly used HLA antigens and
alleles is described in Shankarkumar et al. ((2004) The Human Leukocyte Antigen (HLA)
System, lnt. J. Hum. Genet. 4(2):91-103), incorporated herein by nce. rkumar
et al. also present a brief explanation of HLA nomenclature used in the art. Additional
information regarding HLA nomenclature and various HLA alleles can be found in
Holdsworth et al. (2009) The HLA dictionary 2008: a summary of HLA—A, —B, -C, -
DRB1/3/4/5, and DQB1 alleles and their association with serologically defined HLA-A, -B, —
C, -DR, and —DQ antigens, Tissue Antigens 73:95-170, and a recent update by Marsh et al.
(2010) Nomenclature for factors of the HLA system, 2010, Tissue Antigens —455, both
incorporated herein by reference. Thus, the human or humanized MHC II polypeptide may
be derived from any functional human HLA molecules described therein.
In one specific aspect, the human portions of the humanized MHC ll complex
described herein are derived from human HLA-DR, e.g., HLA-DR4. Typically, HLA-DR 0L
chains are monomorphic, e.g., the on chain of HLA-DR complex is encoded by A
gene (e.g., HLA-DRa*01 gene). On the other hand, the HLA-DR B chain is polymorphic.
Thus, 4 comprises an 0: chain encoded by A gene and a [3 chain encoded
by HLA—DRB1 gene (e.g., HLA-DRB1*04 gene). As described herein below, HLA-DR4 is
known to be associated with nce of a number of autoimmune diseases, e.g.,
rheumatoid arthritis, type I diabetes, multiple sis, etc. ln one embodiment of the
invention, the HLA-DRA allele is HLA-DRa*01 allele, e.g., HLA-DRa*01:01:01:01. In
another embodiment, the HLA-DRB allele is HLA—DRB1*04, e.g., HLA-DR[51*04:01 :01.
Although the present Examples describe these particular HLA sequences; any le HLA—
DR sequences are encompassed herein, e.g., rphic variants ted in human
population, sequences with one or more conservative or non-conservative amino acid
modifications, nucleic acid sequences differing from the sequences described herein due to
the degeneracy of genetic code, etc.
The human portions of the humanized MHC II complex may be encoded by
nucleotide sequences of HLA alleles known to be associated with common human diseases.
Such HLA alleles e, but are not limited to, HLA-DRB1*O401, O301, —
501, -DQB1*0201,—DRB1*1501,-DRBt*1502, -DQB1*0602, —DQA1*O102, -
DQA1*0201, -DQB1*0202, -DQA1*0501, and combinations thereof. For a summary of HLA
allele/disease associations, see Bakker et al. (2006) A high—resolution HLA and SNP
ype map for disease association studies in the extended human MHC, Nature
Genetics 38:1166-72 and Supplementary Information, incorporated herein by nce.
In one , a non-human portion of the chimeric human/non-human MHC II
x comprises transmembrane and/or asmic domains of an endogenous non—
human (e.g., rodent, e.g., mouse, rat, etc.) MHC II complex. Thus, a man portion of
the chimeric human/non-human MHC II or polypeptide may comprise transmembrane and/or
cytoplasmic domains of an endogenous non—human MHC II on polypeptide. A man
portion of the ic human/non-human MHC II [3 polypeptide may comprise
transmembrane and/or cytoplasmic domains of an endogenous non-human MHC II B
polypeptide. In one , the animal is a mouse, and non-human portions of the chimeric
0t and [3 polypeptides are derived from a mouse H-2E protein. Thus, non—human portions of
the ic a and t3 ptides may comprise transmembrane and asmic domains
derived from a mouse H-2E protein. Although specific H-2E sequences are contemplated in
the Examples, any suitable sequences, e.g., polymorphic variants, conservative/non-
conservative amino acid tutions, etc., are encompassed herein.
In various aspects of the invention, the sequence(s) encoding a chimeric
human/non-human MHC II complex are located at an endogenous non—human MHC II locus
(e.g., mouse H-2A and/or H—2E locus). In one embodiment, this results in a replacement of
an endogenous MHC II gene(s) or a portion thereof with a nucleotide sequence(s) encoding
a human or humanized MHC II protein, e.g., a chimeric gene encoding a chimeric
human/non-human MHC II protein described herein. Since the nucleotide sequences
encoding MHC II on and [3 polypeptides are located in proximity to one r on the
chromosome, a replacement can be designed to target the two genes either independently
or together; both of these possibilities are encompassed herein. In one embodiment, the
replacement comprises a replacement of an endogenous nucleotide sequence encoding an
MHC II or and [3 polypeptides with a nucleotide sequence encoding a chimeric human/non-
human MHC 0L polypeptide and a chimeric human/non-human MHC [3 polypeptide. In one
aspect, the replacement comprises ing nucleotide sequences representing one or
more (e.g., two) endogenous MHC II genes. Thus, the non-human animal contains a
chimeric human/non-human nucleotide sequence at an endogenous MHC II locus, and
expresses a chimeric human/non—human MHC ll protein from the endogenous non—human
locus.
Thus, provided herein is a non-human animal comprising at an endogenous MHC
ll gene locus a first nucleotide sequence encoding a chimeric non-human MHC ll 0.
polypeptide and a second nucleotide sequence encoding a chimeric human/non-human
MHC ll {5 polypeptide, n a human n of the chimeric human/non-human MHC II or
polypeptide comprises a human MHC ll or extracellular domain and a human portion of the
chimeric human/non-human MHC II [3 polypeptide comprises a human MHC ll 0 extracellular
domain, and n the chimeric human/non-human MHC II or and MHC ll [3 polypeptides
form a functional MHC ll x on a surface of a cell.
A chimeric human/non-human polypeptide may be such that it comprises a
human or a non-human leader l) ce. in one embodiment, the chimeric MHC ll
0t polypeptide comprises a non—human leader sequence of an endogenous MHC II or
polypeptide. In one embodiment, the chimeric MHC ll [5 polypeptide comprises a non-
human leader sequence of an endogenous MHC ll B polypeptide. In an alternative
embodiment, the chimeric MHC II on and/or MHC ll {3 polypeptide comprises a non-human
leader sequence of MHC ll or and/or MHC ll [3 polypeptide, respectively, from another non-
human animal, e.g., another rodent or another mouse strain. Thus, the nucleotide sequence
encoding the chimeric MHC II or and/or MHC ll (3 ptide may be operably linked to a
tide ce encoding a non-human MHC II 0. and/or MHC ll [3 leader sequence,
respectively. in yet another embodiment, the chimeric MHC II or and/or MHC II 13 polypeptide
comprises a human leader ce of human MHC ll 0L and/or human MHC ll [3
polypeptide, respectively (e.g., a leader sequence of human HLA-DRA and/or human HLA-
DRB1*O4, respectively).
A chimeric human/non-human MHC ll 0: and/or MHC ll [3 polypeptide may
comprise in its human portion a complete or substantially complete ellular domain of a
human MHC II or and/or human MHC II [3 polypeptide, respectively. Thus, a human portion
may comprise at least 80%, preferably at least 85%, more preferably at least 90%, e.g., 95%
or more of the amino acids encoding an extracellular domain of a human MHC ll or and/or
human MHC ll [3 polypeptide (e.g., human HLA-DRA and/or human HLA-DR[31*04). In one
example, substantially complete extracellular domain of the human MHC II on and/or human
MHC II [3 polypeptide lacks a human leader sequence. In r example, the chimeric
2012/062029
human/non-human MHC II 0t and/or the chimeric human/non-human MHC II [3 polypeptide
comprises a human leader sequence.
Moreover, the ic MHC II on and/or MHC Ii (3 polypeptide may be expressed
under the control of endogenous non-human promoter and regulatory elements, e.g., mouse
MHC II 0t and/or MHC II [3 regulatory elements, respectively. Such arrangement will facilitate
proper expression of the chimeric MHC II polypeptides in the non-human animal, e.g., during
immune response in the non—human animal.
The genetically ed non-human animal may be selected from a group
consisting of a mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat,
chicken, cat, dog, ferret, e (e.g., marmoset, rhesus ). For the non-human
animals where suitable genetically modifiable ES cells are not readily available, other
methods are employed to make a non-human animal comprising the genetic cation.
Such methods include, e.g., modifying a non—ES cell genome (e.g., a fibroblast or an
induced pluripotent cell) and employing nuclear transfer to transfer the modified genome to a
suitable cell, e.g., an oocyte, and gestating the modified cell (e.g., the modified oocyte) in a
non-human animal under suitable ions to form an embryo.
In one aspect, the non—human animal is a mammal. In one aspect, the nonhuman
animal is a small mammal, e.g., of the superfamily Dipodoidea or Muroidea. In one
embodiment, the genetically ed animal is a rodent. In one embodiment, the rodent is
selected from a mouse, a rat, and a hamster. In one embodiment, the rodent is selected
from the superfamily Muroidea. In one embodiment, the genetically modified animal is from
a family ed from Calomyscidae (e.g., like hamsters), Cricetidae (e.g., hamster,
New World rats and mice, voles), Muridae (true mice and rats, s, spiny mice, d
rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice),
Platacanthomyidae (e.g., spiny dormice), and SpaIacidae (e.g., mole rates, bamboo rats,
and zokors). In a specific embodiment, the genetically modified rodent is selected from a
true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat. In one
embodiment, the cally modified mouse is from a member of the family Muridae. In
one embodiment, the animal is a rodent. In a specific embodiment, the rodent is selected
from a mouse and a rat. In one embodiment, the non-human animal is a mouse.
In a specific ment, the non-human animal is a rodent that is a mouse of a
C57BL strain ed from C57'BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, 057BL/6,
C57BL/SJ, C57BL/GByJ, C57BL/6NJ, C57BL/10, C57BL/1OScSn, C57BL/10Cr, and
C57BL/Ola. In another embodiment, the mouse is a 129 strain selected from the group
consisting ofa strain that is 129P1, 129P2, 129P3, 129X1, 12981 (e.g., 12981/SV,
12981/Svlm), 12982, 12984, 12985, 12989/8vaH, 12986 (129/8vaTac), 12987, 12988,
129T1, 129T2 (see, e.g., Festing et al. (1999) Revised nomenclature for strain 129 mice,
Mammalian Genome , see also, Auerbach et al (2000) Establishment and a
Analysis of 129/8va- and 6-Derived Mouse Embryonic Stem Cell Lines). In a
specific embodiment, the genetically modified mouse is a mix of an aforementioned 129
strain and an aforementioned C57BL/6 strain. In another specific embodiment, the mouse is
a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 strains. In a specific
embodiment, the 129 strain of the mix is a 12986 (129/8vaTac) strain. In another
embodiment, the mouse is a BALB strain, e.g., BALB/c strain. In yet another embodiment,
the mouse is a mix of a BALB strain and another entioned strain.
In one embodiment, the man animal is a rat. In one embodiment, the rat
is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344,
F6, and Dark Agouti. In one embodiment, the rat strain is a mix of two or more strains
selected from the group consisting of Wistar, LEA, Sprague , Fischer, F344, F6, and
Dark Agouti.
Thus, in one embodiment, the invention relates to a genetically modified mouse
that comprises in its genome a nucleotide sequence encoding a chimeric mouse
MHC II complex, e.g., chimeric human/mouse MHC II on and [3 polypeptides. In one
embodiment, a human portion of the chimeric human/mouse MHC II a polypeptide
comprises a human MHC II a peptide binding or extracellular domain and a human portion
of the chimeric human/mouse MHC II {5 polypeptide comprises a human MHC II [5 peptide
g or extracellular . In some embodiments, the mouse does not express a
peptide binding or an extracellular domain of endogenous mouse oz and/or[3 polypeptide
from an endogenous mouse locus (e.g., H-2A and/or H-2E locus). In some embodiments,
the mouse comprises a genome that lacks a gene that encodes a functional MHC class II
molecule comprising an H-2Ab1, H-2Aa, H—2Eb1, H—2Eb2, H-2Ea, and a combination
thereof. The e-binding domain of the human MHC II 0L polypeptide may se (11
domain and the e-binding domain of the human MHC II B polypeptide may comprise a
[51 domain; thus, the peptide-binding domain of the chimeric MHC II complex may comprise
human a1 and [31 domains. The extracellular domain of the human MHC II 0t ptide
may comprise (11 and a2 domains and the extracellular domain of the human MHC II [3
polypeptide may comprise [51 and {32 domains; thus, the extracellular domain of the chimeric
MHC II complex may comprise human a1, a2, [31 and [32 domains. In one embodiment, the
mouse n of the chimeric MHC II x comprises transmembrane and cytosolic
domains of mouse MHC II, e.g. mouse H-2E (e.g., transmembrane and cytosolic domains of
mouse H-2E or and [3 chains).
ore, in one embodiment, a genetically modified mouse is provided, wherein
the mouse comprises at an endogenous mouse MHC II locus a first nucleotide sequence
encoding a chimeric human/mouse MHC II 0L ptide and a second nucleotide sequence
encoding a chimeric human/mouse MHC II [3 polypeptide, wherein a human portion of the
chimeric MHC II a ptide ses an extracellular domain derived from an or
polypeptide of a human HLA-DR4 protein and the human portion of the chimeric MHC II B
polypeptide comprises an ellular domain derived from a [3 polypeptide of a human
HLA—DR4 protein, wherein a mouse portion of the chimeric MHC II or polypeptide comprises
transmembrane and cytoplasmic domains of a mouse H—2E or chain and a mouse portion of
the chimeric MHC II {3 polypeptide comprises transmembrane and asmic domains of a
mouse H—2E [3 chain, and wherein the mouse expresses a functional ic HLA—DR4/H-
2E MHC II complex. In one embodiment the chimeric HLA—DR4/H-2E MHC II x
comprises an MHC II a chain that includes extracellular domains (e.g., at, and (12 domains)
derived from HLA—DR4 protein RA a1, and (x2 domains) and transmembrane and
cytoplasmic domains from a mouse H-2E 0c chain, as well as an MHC II [3 chain that includes
extracellular domains (e.g., [31 and [32 domains) derived from HLA—DR4 (HLA—DR[31*O4 [31
and [52 domains) and embrane and cytoplasmic domains from mouse H-2E (3 chain.
In one aspect, the mouse does not express functional nous H-2A and H-2E
polypeptides from their endogenous mouse loci (e.g., the mouse does not express H-2Ab1,
H-2Aa, H—2Eb1, H-2Eb2, and H-2Ea polypeptides). In various embodiments, expression of
the first and second nucleotide sequences is under the control of respective endogenous
mouse promoters and regulatory elements. In various embodiments of the invention, the
first and the second nucleotide ces are located on the same chromosome. In some
aspects, the mouse comprises two copies of the chimeric MHC II locus containing the first
and the second nucleotide sequences, while in other aspects, the mouse ses one
copy of the MHC II locus containing the first and the second nucleotide sequences. Thus,
the mouse may be homozygous or heterozygous for the chimeric MHC II locus containing
the first and the second nucleotide sequences. In various embodiments, the first and the
second nucleotide sequences are comprises in the ne of the mouse.
In some embodiments described herein, a mouse is ed that comprises a
ic MHC II locus at an endogenous mouse MHC II locus, e.g., via replacement of
endogenous mouse H-2A and H—2E genes. In some aspects, the chimeric locus comprises
a nucleotide sequence that encodes an extracellular domain of a human HLA—DRA and
transmembrane and cytoplasmic domains of a mouse H-2E a chain, as well as an
extracellular domain of a human HLA-DRB1*O4 and transmembrane and cytoplasmic
domains of a mouse H—2E [3 chain. The s domains of the chimeric locus are linked in
such a fashion that the locus expresses a functional chimeric human/mouse MHC II
complex.
In various embodiments, a non-human animal (e.g., a rodent, e.g., a mouse or
rat) that expresses a onal chimeric MHC M protein from a chimeric MHC II locus as
described herein displays the chimeric protein on a cell surface. In one embodiment, the
non-human animal expresses the chimeric MHC M protein on a cell surface in a cellular
distribution that is the same as observed in a human. In one aspect, the cell displays a
peptide nt (antigen fragment) bound to an extracellular portion (e.g., human HLA-DR4
extracellular portion) of the ic MHC II n.
In various embodiments, a cell displaying the chimeric MHC II protein, e.g., HLA—
DR4/H-2E protein, is an antigen-presenting cell (APC) e.g., a macrophage, a tic cell,
or a B cell. In some embodiments, the e nt presented by the chimeric protein is
derived from a tumor. In other embodiments, the peptide fragment presented by the
chimeric MHC II protein is derived from a pathogen, e.g., a bacterium, a virus, or a parasite.
The chimeric MHC II protein bed herein may interact with other proteins on
the surface of the same cell or a second cell. In some embodiments, the chimeric MHC II
protein interacts with endogenous non—human proteins on the surface of said cell. The
chimeric MHC M protein may also interact with human or humanized proteins on the surface
of the same cell or a second cell. In some embodiments, the second cell is a T cell, and the
chimeric MHC II protein interacts with T cell receptor (TCR) and its co—receptor CD4. In
some embodiments, the T cell is an nous mouse T cell. In other embodiments, the T
cell is a human T cell. In some embodiments, the TCR is a human or humanized TCR. In
additional ments, the CD4 is a human or humanized CD4. In other embodiment,
either one or both of TCR and CD4 are non-human, e.g., mouse or rat.
In one embodiment, a genetically modified non—human animal as described
herein is provided that does not develop tumors at a higher rate than a wild-type animal that
lacks a chimeric MHC II gene. In some embodiments, the animal does not develop
hematological malignancies, e.g., various T and B cell mas, Ieukemias, composite
lymphomas (e.g., n’s lymphoma), at a higher rate than the wild-type animal.
In addition to a genetically engineered non-human animal, a non-human embryo
(e.g., a , e.g., a mouse or a rat embryo) is also provided, wherein the embryo
comprises a donor ES cell that is derived from a non-human animal (e.g., a rodent, e.g., a
mouse or a rat) as described herein. In one , the embryo comprises an ES donor cell
that comprises the chimeric MHC II gene, and host embryo cells.
Also provided is a , wherein the tissue is derived from a non-human animal
(e.g., a rodent, e.g., a mouse or a rat) as described herein, and expresses the chimeric MHC
II protein (e.g., HLA—DR4/H-2E n).
In addition, a non-human cell isolated from a non-human animal as described
herein is provided. In one embodiment, the cell is an ES cell. In one embodiment, the cell is
an antigen—presenting cell, e.g., dendritic cell, macrophage, B cell. In one embodiment, the
cell is an immune cell. In one ment, the immune cell is a lymphocyte.
Also provided is a non-human cell comprising a chromosome or nt thereof
of a non-human animal as described herein. In one embodiment, the non-human cell
comprises a nucleus of a non-human animal as described herein. In one embodiment, the
non—human cell comprises the chromosome or fragment thereof as the result of a nuclear
transfer.
In one aspect, a non-human induced pluripotent cell comprising gene encoding a
chimeric MHC II n (e.g., HLA—DR4/H-2E n) as described herein is provided. In
one embodiment, the induced pluripotent cell is derived from a non-human animal as
described herein.
In one aspect, a hybridoma or quadroma is provided, derived from a cell of a
man animal as described herein. In one embodiment, the non-human animal is a
mouse or rat.
In one aspect, an in vitro preparation is provided that comprises a first cell that
bears a chimeric human/rodent MHC II surface protein that comprises a bound peptide to
form a chimeric human/rodent MHC ll/peptide complex, and a second cell that binds the
ic human/rodent MHC ll/peptide complex. In one ment, the second cell
comprises a human or humanized T-cell receptor, and in one embodiment r comprises
a human or humanized CD4. In one embodiment, the second cell is a rodent (e.g., mouse
or rat) cell comprising a human or humanized T—cell receptor and a human or humanized
CD4 protein. In one embodiment, the second cell is a human cell.
Also provided is a method for making a genetically engineered man
animal (e.g., a genetically engineered rodent, e.g., a mouse or rat) described herein. The
method for making a genetically engineered non—human animal results in the animal whose
genome comprises a nucleotide sequence encoding a chimeric MHC II protein (e.g.,
chimeric MHC II on and [3 polypeptides). In one embodiment, the method results in a
genetically engineered mouse, whose genome comprises at an endogenous MHC II locus a
nucleotide sequence encoding a chimeric human/mouse MHC II protein, wherein a human
portion of the ic MHC ll protein comprises an extracellular domain of a human HLA-
DR4 and a mouse portion comprises transmembrane and cytoplasmic domains of a mouse
H-2E. In some embodiments, the method utilizes a targeting uct made using
VELOCIGENE® technology, introducing the uct into ES cells, and introducing
targeted ES cell clones into a mouse embryo using VELOClMOUSE® technology, as
described in the Examples. in one embodiment, the ES cells are a mix of 129 and C57BL/6
mouse strains; in one embodiment, the ES cells are a mix of BALB/c and 129 mouse strains.
A nucleotide construct used for ting genetically engineered non—human
animals described herein is also provided. in one aspect, the nucleotide uct
comprises: 5' and 3’ man homology arms, a DNA fragment comprising human HLA—
DR or and B chain sequences, and a selection cassette flanked by recombination sites. In
one embodiment, the human HLA—DR or and {5 chain sequences are genomic sequences
that comprise introns and exons of human HLA-DR 0L and 6 chain genes. in one
embodiment, the non-human homology arms are homologous to non-human MHC ll
genomic sequence.
In one embodiment, the human HLA-DR a chain sequence comprises an (11 and
a2 domain coding sequence. in a specific embodiment, it comprises, from 5’ to 3’: (x1 exon
(exon 2), a1/oc2 intron (intron 2), and a2 exon (exon 3). in one embodiment, the human
HLA-DR [3 chain sequence comprises a [31 and [32 domain coding sequence. In a specific
embodiment, it comprises, from 5’ to 3’: [31 exon (exon 2), [31/62 intron (intron 2), and [32
exon (exon 3).
A selection Cassette is a nucleotide sequence inserted into a targeting uct
to facilitate ion of cells (e.g., ES cells) that have integrated the construct of interest. A
number of suitable selection cassettes are known in the art. Commonly, a selection cassette
enables positive selection in the presence of a particular otic (e.g., Neo, Hyg, Pur, CM,
SPEC, etc.). in addition, a selection cassette may be d by recombination sites, which
allow deletion of the selection te upon treatment with recombinase enzymes.
Commonly used ination sites are loxP and Fit, recognized by Cre and Flp enzymes,
respectively, but others are known in the art. A ion cassette may be located anywhere
in the construct outside the coding region. In one embodiment, the selection cassette is
located in the [3 chain intron, e.g., BZ/transmembrane domain intron (intron 3).
In one embodiment, 5’ and 3’ homology arms comprise genomic sequence at 5’
and 3’ locations of endogenous non-human MHC II locus. In one embodiment, the 5’
homology arm comprises genomic sequence upstream of mouse H-2Ab1 gene and the 3’
homology arm comprises genomic sequence downstream of mouse H—2Ea gene. In this
embodiment, the construct allows replacement of both mouse H-2E and H-2A genes.
Thus, in one aspect, a nucleotide uct is provided comprising, from 5’ to 3’:
a 5’ gy arm containing mouse genomic sequence upstream of mouse H-2Ab1 gene,
a first nucleotide ce comprising a sequence encoding a ic human/mouse MHC
ll [5 chain, a second nucleotide sequence comprising a sequence ng a chimeric
human/mouse MHC II or chain, and a 3’ homology arm containing mouse genomic sequence
downstream of mouse H-2Ea gene. In a specific embodiment, the first nucleotide sequence
comprising a sequence encoding a chimeric human/mouse MHC II {5 chain comprises
human [31 exon, [SI/[32 , [32 exon, an a selection cassette flanked by recombination
sites inserted in the intronic region n the human [32 exon sequence and the sequence
of a mouse transmembrane domain exon. In a specific embodiment, the second nucleotide
sequence comprising a sequence encoding a chimeric human/mouse MHC II or chain
comprises human a1 exon, (11/012 intron, and human (x2 exon. An exemplary construct of
the invention is ed in (MAID 1680).
Upon completion of gene targeting, ES cells or cally modified non-human
animals are screened to confirm successful incorporation of exogenous nucleotide sequence
of interest or expression of exogenous polypeptide. us techniques are known to
those skilled in the art, and include (but are not limited to) Southern blotting, long PCR,
quantitative PCT (e.g., ime PCR using TAQMAN®), fluorescence in situ hybridization,
Northern blotting, flow cytometry, Western analysis, immunocytochemistry,
histochemistry, etc. In one example, non-human animals (e.g., mice) bearing the
genetic modification of interest can be fied by screening for loss of mouse allele and/or
gain of human allele using a cation of allele assay described in Valenzuela et al.
(2003) High-throughput engineering of the mouse genome coupled with high-resolution
expression is, Nature Biotech. 21 (6):652-659. Other assays that identify a specific
nucleotide or amino acid sequence in the genetically modified animals are known to those
skilled in the art.
The disclosure also provides a method of modifying an MHC II locus of a nonhuman
animal to express a chimeric human/non—human MHC II x described herein.
In one embodiment, the invention provides a method of modifying an MHC II locus of a
mouse to express a chimeric human/mouse MHC II complex comprising replacing at the
WO 63340
endogenous mouse MHC II locus a nucleotide ce encoding a mouse MHC II complex
with a nucleotide sequence encoding a chimeric human/mouse MHC II complex. In a
specific aspect, the nucleotide sequence encoding the chimeric human/mouse MHC II
complex comprises a first nucleotide sequences encoding an extracellular domain of a
human MHC II on chain (e.g., HLA-DR4 or chain) and transmembrane and cytoplasmic
domains of a mouse MHC II a chain (e.g., H-2E or chain) and a second nucleotide sequence
encoding an extracellular domain of a human MHC II B chain (e.g., HLA-DR4 [3 chain) and
transmembrane and asmic domains of a mouse MHC II [5 chain (e.g., H-2E [3 chain,
e.g., H-2Eb1 chain). In some embodiments, the modified mouse MHC II Iocus expresses a
chimeric HLA-DR4/H-2E n.
In one aspect, a method for making a ic human HLA class II/non—human
MHC class II molecule is provided, comprising expressing in a single cell a chimeric HLA-
ADR4/H-2E protein from a nucleotide construct as described herein. In one embodiment, the
nucleotide construct is a viral vector; in a specific embodiment, the viral vector is a lentiviral
vector. In one embodiment, the cell is selected from a CHO, COS, 293, HeLa, and a l
celI expressing a viral nucleic acid sequence (e.g., a PERC.6T"" cell).
In one aspect, a cell that expresses a chimeric HLA-DR4/H-2E protein is
provided. In one embodiment, the cell comprises an sion vector comprising a
chimeric MHC class II sequence as bed herein. In one embodiment, the cell is
selected from CHO, COS, 293, HeLa, and a l cell expressing a viral nucleic acid
sequence (e.g., a PERC.6TM cell).
A chimeric MHC class II molecule made by a non—human animal as described
herein is also provided, wherein the chimeric MHC class II molecule comprises (11, a2, [51,
and [32 domains from a human MHC II protein, e.g., 4 protein, and transmembrane
and cytoplasmic domains from a non-human MHC II protein, e.g., mouse H-2E protein. The
chimeric MHC II complex comprising an extracellular domain of 4 described herein
maybe detected by anti-HLA-DR antibodies. Thus, a cell displaying chimeric human/non-
human MHC II ptide may be detected and/or selected using anti—HLA—DR antibody.
Although the Examples that follow describe a genetically engineered animal
whose genome comprises a replacement of a nucleotide sequence encoding mouse H-2A
and H-2E proteins with a nucleotide sequence encoding a chimeric human/mouse HLA-
2E protein, one skilled in the art would understand that a similar strategy may be
used to introduce chimeras sing other human MHC II genes (HLA-DP and HLA-DQ).
Thus, an additional embodiment of the invention is ed to a genetically ered
animal whose genome comprises a nucleotide sequence encoding a chimeric HLA—DQ/H—ZA
protein. in one ment, the tide sequence encodes a chimeric HLA—DQ2.5/H-2A
protein. in another ment, the nucleotide sequence encodes a chimeric HLA-DQS/H—
2A n. In on, introduction of multiple humanized MHC II molecules (e.g., chimeric
HLA—DR/H—ZE and HLA-DQ/H-ZA) is also contemplated.
Use of Genetically Modified Animals
In s ments, the genetically modified non-human animals bed
herein make APCs with human or humanized MHC II on the cell surface and, as a result,
present peptides derived from cytosolic proteins as epitopes for T cells in a human-like
manner, because substantially all of the components of the complex are human or
humanized. The genetically modified non-human animals of the invention can be used to
study the function of a human immune system in the humanized animal; for identification of
antigens and antigen epitopes that elicit immune response (e.g., T cell epitopes, e.g., unique
human cancer epitopes), e.g., for use in e development; for evaluation of vaccine
candidates and other vaccine strategies; for studying human autoimmunity; for studying
human infectious diseases; and othenrvise for devising better therapeutic strategies based
on human MHC expression.
MHC II complex binds peptides derived from extracellular proteins, e.g.,
extracellular bacterium, neighboring cells, or polypeptides bound by B cell receptors and
internalized into a B cell. Once extracellular proteins enter endocytic pathway, they are
degraded into peptides, and peptides are bound and presented by MHC ll. Once a e
presented by MHC ii is recognized by CD4+ T cells, T cells are activated, proliferate,
differentiate to various T helper es (e.g., TH1, TH2), and lead to a number of events
including activation of macrophage-mediated pathogen killing, B cell proliferation, and
antibody production. Because of MHC II role in immune response, understanding of MHC II
peptide presentation is important in the development of treatment for human pathologies.
r, presentation of antigens in the context of mouse MHC II is only somewhat relevant
to human disease, since human and mouse MHC xes ize antigens differently,
e.g., a mouse MHC II may not recognize the same antigens or may present different
epitopes than a human MHC II. Thus, the most nt data for human pathologies is
obtained through studying the presentation of antigen epitopes by human MHC II.
Thus, in various embodiments, the genetically engineered animals of the present
invention are useful, among other things, for evaluating the capacity of an n to initiate
an immune se in a human, and for generating a diversity of antigens and identifying a
specific antigen that may be used in human vaccine development.
In one aspect, a method for determining antigenicity in a human of a peptide
sequence is provided, sing exposing a genetically modified non-human animal as
described herein to a molecule comprising the peptide sequence, allowing the non-human
animal to mount an immune response, and detecting in the non-human animal a cell that
binds a sequence of the peptide ted by a zed MHC II complex described
herein.
In one aspect, a method for determining whether a peptide will provoke an
immune response in a human is ed, comprising exposing a genetically modified non-
human animal as described herein to the peptide, allowing the non—human animal to mount
an immune response, and ing in the non-human animal a cell that binds a sequence of
the peptide by a chimeric human/non-human MHC class II molecule as described herein. In
one embodiment, the non-human animal following exposure comprises an MHC class II-
restricted CD4+ T cell that binds the peptide.
In one aspect, a method for identifying a human CD4+ T cell epitope is provided,
comprising ng a non—human animal as described herein to an antigen comprising a
putative T cell epitope, allowing the non-human animal to mount an immune response, and
identifying the epitope bound by the MHC class ll-restricted CD4+ T cell.
In one aspect, a method is provided for identifying an antigen that generates a
CD4+ T cell response in a human, comprising exposing a ve antigen to a mouse as
described herein, allowing the mouse to generate an immune response, detecting a CD4+ T
cell response that is specific for the antigen in the context of a human MHC II molecule (e.g.,
an HLA-DR molecule), and identifying the antigen bound by the human MHC ll-restricted
molecule (e.g., human HLA-DR restricted molecule).
In one embodiment, the antigen comprises a bacterial protein. In one
embodiment, the antigen ses a human tumor cell antigen. In one embodiment, the
n comprises a putative e for use in a human, or another biopharmaceutical. In
one embodiment, the antigen comprises a human epitope that generates antibodies in a
human. In yet another embodiment, an antigen comprises a yeast or fungal cell antigen. In
yet another embodiment, an antigen is derived from a human parasite.
In one aspect, a method is ed for determining whether a ve n
contains an epitope that upon exposure to a human immune system will generate an HLA—
DR-restricted immune response (e.g., HLA—DR4-restricted se), comprising ng a
mouse as described herein to the putative antigen and ing an antigen—specific HLA-
DR-restricted (e.g., HLA-DR4-restricted) immune response in the mouse. In another aspect,
a method is provided for determining wherein a ve antigen contains an epitope that
upon exposure to a human immune system will generate an HLA—DQ-restricted response.
Also provided is a method of generating antibodies to an antigen, e.g., an antigen
derived from bacterium, parasite, etc., ted in the context of a human MHC II complex,
comprising exposing a mouse described herein to an antigen, allowing a mouse to mount an
immune response, wherein the immune response comprises antibody tion, and
isolating an antibody that recognizes the antigen presented in the t of human MHC II
complex. In one ment, in order to generate antibodies to the peptide-MHC II, the
MHC II zed mouse is immunized with a peptide—MHC II immunogen.
In one , a method for identifying a T cell receptor variable domain that
recognizes an antigen ted in the context of MHC II (e.g., human tumor antigen, a
vaccine, etc.) is provided, comprising exposing a mouse comprising a zed MHC II
complex described herein to the antigen, allowing the mouse to generate an immune
response, and isolating from the mouse a nucleic acid sequence encoding a variable domain
of a T cell or that binds MHC lI-restricted antigen. In one embodiment, the n is
presented in the context of a humanized MHC II (e.g., human HLA ll ectodomain/mouse
MHC II transmembrane and/or cytoplasmic domain).
The uence of interaction between a T cell and an APC displaying a
peptide in the context of MHC II (e.g., human HLA || ectodomain/mouse MHC II
transmembrane and/or cytoplasmic domain) can be measured by a number of techniques
known in the art, e.g., T cell proliferation assays, cytokine release assays, etc.
In on to the ability to fy antigens and their T cell epitopes from
pathogens or neoplasms, the genetically modified animals of the invention can be used to
identify autoantigens of relevance to human autoimmune disease, and othenlvise study
human autoimmune disease progression. It is known that polymorphisms within the HLA
loci play a role in predisposition to human autoimmune disease. In fact, specific
polymorphisms in HLA-DR and HLA-DQ loci have been identified that correlate with
development of rheumatoid arthritis, type I diabetes, Hashimoto’s thyroiditis, le
sclerosis, myasthenia gravis, Graves' disease, systemic lupus erythematosus, celiac
disease, Crohn’s disease, ulcerative colitis, and other mune disorders. See, e.g.,
Wong and Wen (2004) What can the HLA transgenic mouse tell us about autoimmune
diabetes?, Diabetologia 47:1476-87; Taneja and David (1998) HLA Transgenic Mice as
Humanized Mouse Models of Disease and Immunity, J. Clin. Invest. 101:921—26; Bakker et
al. (2006), supra; and International MHC and Autoimmunity Genetics Network (2009)
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated
diseases, Proc. Natl. Acad. Sci. USA 106:18680-85.
Thus, the methods of making a zed MHC II complex animals described
herein can be used to introduce MHC ll molecules thought to be associated with specific
human mune diseases, and progression of human mune disease can be
studied. In addition, non-human s described herein can be used to develop animal
models of human autoimmune disease. Mice according to the invention ng humanized
MHC II proteins described herein can be used to identify potential autoantigens, to map
epitopes involved in disease progression, and to design strategies for autoimmune disease
modulation.
In addition, the genetically modified animals described herein may be used in the
study of human allergic response. As allergic responses appear to be associated with MHC
II alleles, cally modified animals described herein may be used to determine HLA
restriction of allergen specific T cell response and to develop strategies to combat ic
response.
EXAMPLES
The invention will be further illustrated by the following nonlimiting examples.
These Examples are set forth to aid in the understanding of the ion but are not
intended to, and should not be construed to, limit its scope in any way. The Examples do not
include detailed descriptions of tional s that would be well known to those of
ordinary skill in the art (molecular cloning techniques, etc). Unless indicated otherwise,
parts are parts by weight, molecular weight is average molecular , temperature is
ted in Celsius, and pressure is at or near atmospheric.
Example 1. Deletion of the Endogenous MHC class II H-2A and H-2E Loci
The targeting vector for introducing a deletion of the nous MHC class ll H-
2Ab1, H-2Aa, H-2Eb1, H-2Eb2, and H-2Ea genes was made using VELOCIGENE® genetic
engineering technology (see, 9.9., US Pat. No. 6,586,251 and Valenzuela et al., supra).
Bacterial Artificial Chromosome (BAC) RP23—458i22 (lnvitrogen) DNA was modified to
delete the endogenous MHC class II genes H—2Ab1, H-2Aa, H-2Eb1, H-2Eb2, and H—2Ea.
] Briefly, upstream and downstream homology arms were derived by PCR of
mouse BAC DNA from locations 5’ of the H-2Ab1 gene and 3’ of the H—2Ea gene,
respectively. As depicted in these homology arms were used to make a cassette
that deleted ~79 kb of RP23-458i22 comprising genes H-2Ab1, H-2Aa, H-2Eb1, H-2Eb2,
and H-2Ea of the MHC class ll locus by bacterial homologous recombination (BHR). This
region was replaced with a hygromycin cassette flanked by lox66 and lox71 sites. The final
targeting vector from 5’ to 3’ included a 34 kb homology arm comprising mouse genomic
sequence 5’ to the H-2Ab1 gene of the endogenous MHC class II locus, a 5’ on66 site, a
hygromycin cassette, a 3’ lox71 site and a 63 kb homology arm comprising mouse genomic
sequence 3’ to the H—2Ea gene of the endogenous MHC class II locus (MAID 5111, see FIG.
The BAC DNA targeting vector ibed above) was used to electroporate
mouse ES cells to create modified ES cells comprising a deletion of the endogenous MHC
class II locus. Positive ES cells containing a d endogenous MHC class II locus were
identified by the tative PCR assay using TAQMANT'V' probes (Lie and Petropoulos
(1998) Curr. Opin. Biotechnology 9:43-48). The upstream region of the deleted locus was
confirmed by PCR using primers 5111U F CGCCAGGCTGTAAC; SEQ ID N0:1)
and 5111U R (GGAGAGCAGGGTCAGTCAAC; SEQ ID N0:2) and probe 5111U P
(CACCGCCACTCACAGCTCCTTACA; SEQ ID NO:3), whereas the downstream region of
the deleted locus was confirmed using primers 5111D F (GTGGGCACCATCTTCATCATTC;
SEQ ID NO:4) and 5111D R (CTTCCTTTCCAGGGTGTGACTC; SEQ ID NO:5) and probe
5111D P (AGGCCTGCGATCAGGTGGCACCT; SEQ ID N016). The presence of the
ycin cassette from the targeting vector was confirmed using primers HYGF
(TGCGGCCGATCTTAGCC; SEQ ID N027) and HYGR (TTGACCGATTCCTTGCGG; SEQ
ID NO:8) and probe HYGP (ACGAGCGGGTTCGGCCCATTC; SEQ ID NO:9). The
nucleotide sequence across the upstream deletion point (SEQ ID N0:10) included the
following, which indicates endogenous mouse sequence upstream of the deletion point
(contained within the parentheses below) linked uously to cassette sequence present
at the on point: (TTTGTAAACA AAGTCTACCC AGAGACAGAT GACAGACTTC
AGCTCCAATG CTGATTGGTT CCTCACTTGG GACCAACCCT) CTCGAGTACC
GTTCGTATAA TGTATGCTAT TTAT ATGCATCCGG GAGG. The
nucleotide sequence across the downstream deletion point (SEQ ID N0:11) included the
following, which indicates cassette sequence contiguous with nous mouse sequence
downstream of the deletion point ined within the heses below): CCTCGACCTG
CAGCCCTAGG ATAACTTCGT ATAATGTATG CTATACGAAC GGTAGAGCTC
(CACAGGCATT TGGGTGGGCA GGGATGGACG GTGACTGGGA CAATCGGGAT
GCAT AGAATGGGAG TTAGGGAAGA). Positive ES cell clones were then used
to implant female mice using the VELOCIMOUSE® method (described below) to generate a
litter of pups containing a deletion of the endogenous MHC class II locus.
Targeted ES cells described above were used as donor ES cells and introduced
into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (see, 9.9., US Pat. No.
WO 63340
7,294,754 and Poueymirou et al. (2007) F0 generation mice that are essentially fully derived
from the donor gene-targeted ES cells allowing immediate phenotypic analyses, Nature
Biotech. 25(1):91-99). Mice bearing a deletion of H-2Ab1, H—2Aa, H-2Eb1, H-2Eb2, and H-
2Ea genes in the endogenous MHC class II locus were identified by genotyping using a
modification of allele assay (Valenzuela et al., supra) that detected the presence of the
hygromycin cassette and confirmed the absence of endogenous MHC class II sequences.
Mice bearing a deletion of H-2Ab1, H-2Aa, H-2Eb1, H-2Eb2, and H-2Ea genes in
the endogenous MHC class II locus can be bred to a Cre r mouse strain (see, e.g.,
ational Patent Application Publication No. ) in order to remove any
loxed hygromycin te introduced by the targeting vector that is not d, e.g., at the
ES cell stage or in the . Optionally, the hygromycin te is retained in the mice.
Example 2. Generation of Large Targeting Vector (LTVEC) Comprising Humanized H-
2Eb1 and H-2Ea Genes
A targeting vector to introduce humanized MHC II sequences was designed as
ed in Using VELOCIGENE® genetic engineering technology, Bacterial
Artificial Chromosome (BAC) RP23-458i22 DNA was ed in various steps to: (1) create
a vector comprising a functional l-E on exon 1 from BALB/c H-2Ea gene (); (2) create
a vector comprising replacement of exons 2 and 3 of mouse l-E (3 gene with those of human
DRfi1*O4 and replacement of exons 2 and 3 of mouse l-E or with those of human DRa1*01
(FIGS. 48); (3) create a vector carrying exons 2 and 3 of human DR[31*04 amongst
remaining mouse I—E B exons, and exons 2 and 3 of human DRoc1*O1 amongst remaining
mouse l—E 0L exons ing a functional l—E on exon 1 from BALB/c mouse (step (1) (); and (4) remove a cryptic splice site in the vector generated in (3) ().
Specifically, because in the C57Bl/6 mice, the l-E 0t gene is a pseudogene due to
the presence of a non-functional exon 1, first, a vector comprising a functional l-E or exon 1
from BALB/c H—2Ea gene was created (). RP23-458i22 BAC was modified by
bacterial homologous recombination (1 .BHR) to replace chloramphenicol resistance gene
with that of spectromycin. The resultant vector was r ed by BHR to e the
entire l—A and l-E coding region with a neomycin cassette flanked by recombination sites
(2.BHR). Another round of BHR (3. BHR) with the construct comprising an exon encoding
BALB/c l-Ea leader (exon 1) and chloramphenicol gene flanked by Pl-Scel and l—Ceul
restriction sites resulted in a vector comprising a functional BALB/c H-2Ea exon 1.
Independently, in order to generate a vector comprising replacement of exons 2
and 3 of mouse l—E [3 gene with those of human DR|31*04 and replacement of exons 2 and 3
WO 63340
of mouse l-E or with those of human DRa1*O1, RP23—458i22 BAC was modified via several
homologous ination steps, 4. BHR - 8. BHR (), The resultant nucleic acid
sequence was flanked by Pl—Scel/I-Ceul restriction sites to allow ligation into the construct
carrying BALB/c I-Eoc exon 1, mentioned above ().
The sequence of the final construct depicted in contained a c splice
site at the 3’ end of the BALB/c intron. Several BHR steps (11. BHR — 12. BHR) followed by
a deletion step were performed to obtain the final targeting vector (MAID 1680) that was
used to electroporate into ES cells ().
In detail, the final ing vector (MAID 1680), from 5’ to 3’, was comprised of a
’ mouse homology arm consisting of ~26 kb of mouse genomic sequence ending just
am of the H-2Ab1 gene of the endogenous MHC class II locus; an ~59 kb insert
containing the humanized MHC II [3 chain gene (humanized H—2Eb1 gene) and humanized
MHC II a chain gene (humanized H-2Ea gene) and a floxed neomycin cassette; and a 3’
mouse homology arm consisting of ~57 kb of mouse genomic sequence beginning just
ream of the H—2Ea gene of the endogenous MHC class II locus. The nucleotide
sequence across the junction between the 5’ arm and the insert (SEQ ID NO:12) included
the following: (TGCTGATTGG TTCCTCACTT GGGACCAACC C) TAAGCTTTA
TCTATGTCGG GTGCGGAGAA AGAGGTAATG AAATGGCACA AGGAGATCAC
AAAC CAAACTCGCC, where the italicized sequence is a unique PI-Scel site, and
mouse genomic sequence in the 5’ homology arm is in parentheses. The nucleotide
sequence across the junction between the insert and the 3’ arm (SEQ ID NO:13) included
the following: CACATCAGTG GAAT AAATTAAAAT CGCTAATATG AAAATGGGG
(ATTTGTACCT GTGA AGGCTGGGAA GACTGCTTTC AAGGGAC), where the
mouse genomic ce in the 3’ homology arm is in heses.
Within the ~59 kb insert, the H-2Eb1 gene was modified as s: a 5136 bp
region of H-2Eb1, including the last 153 bp of intron1, exon 2, intron 2, exon 3, and the first
122 bp of intron 3, was replaced with the 3111 bp homologous region of human HLA—
DRB1*04, including the last 148 bp of intron 1, exon 2, intron 2, exon 3, and the first 132 bp
of intron 3. At the junction between the human and mouse sequences of intron 3, a cassette
consisting of a 5’ lox2372 site, UbC promoter, neomycin resistance gene, and a 3’ lox2372
site, was inserted. The resulting gene encoded a chimeric HLA—DRB1*04/H-2Eb1 protein
comprised of the mouse H-2Eb1 leader, the human [:31 and [32 s from DRB1*04, and
the mouse transmembrane domain and cytoplasmic tail. The nucleotide sequence across
the mouse/human junction in intron 1 (SEQ ID NO:14) included the following:
(TCCATCACTT CACTGGGTAG CACAGCTGTA ACTGTCCAGC CTG) GGTACCGAGC
2012/062029
TCGGA TCCAC TAGTAACGGC CGCCAGTGTG CTGGAATTC GCCCTTGATC
GAGCTCCCTG GGCTGCAGGT GGTGGGCGTT GCGGGTGGGG CCGGTTAA, where the
italicized sequence is a multiple cloning site introduced during the g steps, and the
mouse intron 1 sequences are in parentheses. The nucleotide sequence across the junction
between the human intron 3 and neomycin cassette (SEQ ID NO:15) included the following:
CATCA GAAGGGCACC GGT) ATAACTT CGTA ATCCTATACG
AAGTTATATG CATGGCCTCC GCGCCGGGTT, where the 5’ |ox2372 site is italicized, and
human intron 3 sequence is in parentheses. The nucleotide sequence across the junction
between the neomycin cassette and mouse intron 3 (SEQ ID NO:16) included the following:
ATAACTTCGTATAAGGTATC CTATACGAAG TTA G (TGGCTTACAG
GTAGGTGCGT GAAGCTTCTA CAGT TGCCCCCTGG), where the 3’ lox2372 site
is italicized, and the mouse intron 3 sequence is in parentheses.
Also within the ~59 kb insert, the H-2Ea gene was modified as follows: a 1185 bp
region of H-2Ea, including the last 101 bp of intron1, exon 2, intron 2, exon 3, and the first 66
bp of intron 3, was replaced with the 1189 bp homologous region of human HLA—DRA1 *01,
including the last 104 bp of intron 1, exon 2, intron 2, exon 3, and the first 66 bp of intron 3.
As described above, because exon 1 of the 057BL/6 allele of H-2Ea contains a deletion
which s the gene nonfunctional, H-2Ea exon 1 and the remainder of intron 1 were
replaced with the equivalent 2616 bp region from the BALB/c allele of H-2Ea, which is
functional. The resulting gene encoded a chimeric H-2Ea/HLA-DRA1*O1 n comprised
of the mouse H-2Ea leader from , the human a1 and a2 domains from DRA1*O1,
and the mouse transmembrane domain and cytoplasmic tail. The nucleotide sequence
across the mouse/human junction in intron 1 (SEQ lD NO:17) included the following:
(CTGTTTCTTC CCTAACTCCC ATTCTATGCT CTTCCATCCC GA) CCGCGGCCCA
ATCTCTCTCC ACTACTTCCT GCCTACATGT ATGTAGGT, where the ized sequence
is a restriction enzyme site introduced during the cloning steps, and the BALB/c intron 1
sequences are in parentheses. The nucleotide sequence across the human/mouse junction
in intron 3 (SEQ lD NO:18) included the ing: CAAGGTTTCC TCCTATGATG
TGAA ACTCGGGGCC GGCC (AGCATTTAAC AGTACAGGGA TGGGAGCACA
GCTCAC), where the italicized sequence is a ction enzyme site introduced during the
cloning steps, and the mouse intron 3 sequences are in parentheses. The nucleotide
sequence across the CS7BL/6-BALB/c junction 5’ of exon 1 (SEQ ID NO:19) included the
following: (GAAAGCAGTC TTCCCAGCCT TCACACTCAG AGGTACAAAT) CCCCATTTTC
ATATTAGCGA TTTTAATTTA TTCTAGCCTC, where the CS7BL/6-specific sequences are
in parentheses. The nucleotide sequence across the BALB/c-C57BL/6 junction 3’ of exon 1
(SEQ ID NO:20) included the following: TCTTCCCTAA CTCCCATTCT ATGCTCTTCC
ATCCCGA CCG CGG (CCCAATC TCTCTCCACT ACTTCCTGCC TACATGTATG), where
Sacll restriction site is italicized, and C57BL/6 ces are in parenthesis.
Example 3. Generation of Humanized MHC II Mice
] Simplified diagrams of the strategy for generating humanized MHC ll mice using
the vector of Example 2 are presented in Fle. 5 and 8.
Specifically, MAID1680 BAC DNA (described above) was used to oporate
MAlD5111 ES cells to create modified ES cells comprising a replacement of the
endogenous mouse l-A and l—E loci with a genomic nt comprising a ic human
DR4/mouse l-E locus. Positive ES cells containing deleted endogenous l—A and l-E loci
replaced by a c fragment comprising a chimeric human DR4/mouse l-E locus were
identified by a quantitative PCR assay using TAQMANT'V' probes (Lie and Petropoulos,
supra). The insertion of the human DRoc sequences was confirmed by PCR using primers
hDRA1F (CTGGCGGCTTGAAGAATTTGG; SEQ ID NO:21), hDRA1R
TTTCCAGGTTGGCTTTGTC; SEQ ID NO:22), and probe hDRA1P
(CGATTTGCCAGCTTTGAGGCTCAAGG; SEQ ID NO:23). The insertion of the human DR[3
sequences was confirmed by PCR using primers hDRB1 F TGGGTGCTCCACTTG;
SEQ ID NO:24), hDRB1R (GACCCTGGTGATGCTGGAAAC; SEQ ID N025), and probe
hDRB1 P (CAGGTGTAAACCTCTCCACTCCGAGGA; SEQ lD NO:26).The loss of the
hygromycin cassette from the targeting vector was confirmed with s HYGF
(TGCGGCCGATCTTAGCC; SEQ ID NO:7) and HYGR (TTGACCGATTCCTTGCGG; SEQ
ID NO:8) and probe HYGP (ACGAGCGGGTTCGGCCCATTC; SEQ ID NO:9).
Positive ES cell clones were then used to implant female mice using the
MOUSE® method (supra) to generate a litter of pups containing a replacement of
the endogenous l-A and l-E loci with a chimeric human DR4/mouse l—E locus. ed ES
cells described above were used as donor ES cells and introduced into an 8—cell stage
mouse embryo by the VELOCIMOUSE® method. Mice bearing a chimeric human
DR4/mouse l-E locus were identified by genotyping using a modification of allele assay
(Valenzuela et al., supra) that detected the presence of a chimeric human DR4/mouse l-E
locus.
Mice bearing a chimeric human DR4/mouse l-E locus can be bred to a Cre
deletor mouse strain (see, e.g., International Patent Application Publication No. WO
2009/114400) in order to remove any loxed neomycin cassette introduced by the targeting
vector that is not removed, e.g., at the ES cell stage or in the embryo (See .
Example 4. Expression of the ic HLA-DR4 in cally Modified Mice
Spleens from WT or heterozygous humanized HLA-DR4 mice (“1681 HET”) were
perfused with Collagenase D (Roche Bioscience) and erythrocytes were lysed with ACK lysis
buffer. Splenocytes were cultured for two days with 25 micrograms/mL poly(I:C) to stimulate
the expression of MHC-II genes. Cell surface expression of human HLA-DR4 was analyzed
by FACS using fluorochrome-conjugated anti-CD3 (17A2), anti-CD19 (1D3), anti-CD11c
(N418), anti-F480 (BM8), anti-I-A/I-E (M15) and anti-HLADR (L243). Flow cytometry was
performed using BD-LSRII. Expression of human 4 was clearly detectable on the
surface of CD19+ B cells and was significantly upregulated upon stimulation by toll-like
receptor agonist poly(I:C) (see .
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than
routine experimentation, many equivalents of the specific embodiments of the invention
described herein. Such lents are ed to be encompassed by the following claims.
Entire contents of all non-patent documents, patent applications and patents cited
throughout this application are incorporated by reference herein in their entirety.
Where the terms “comprise”, “comprises”, “comprised” or “comprising” are used in
this specification (including the claims) they are to be interpreted as specifying the presence
of the stated features, rs, steps or components, but not precluding the presence of one
or more other features, integers, steps or components, or group thereof.
The sion of documents, acts, materials, devices, articles and the like is
included in this specification solely for the e of providing a context for the present
invention. It is not suggested or represented that any or all of these matters formed part of
the prior art base or were common general dge in the field relevant to the present
ion as it existed before the priority date of each claim of this application.
Claims (18)
1. A non-human animal comprising at an endogenous Major Histocompatibility Complex II (MHC II) gene locus a nucleotide sequence encoding a ic human/non-human MHC II polypeptide and/or comprising at an endogenous MHC II β gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II β polypeptide, wherein a human portion of the chimeric non-human MHC II polypeptide comprises a human MHC II 2 ellular domain, and/or a human portion of the chimeric human/non-human MHC II β polypeptide comprises human MHC II β2 domains, and wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal.
2. The animal of claim 1, wherein the nucleotide sequence encoding a chimeric human/non-human MHC II polypeptide is expressed under regulatory control of endogenous man MHC II promoter and tory elements and/or the tide sequence encoding a chimeric human/non-human MHC II β polypeptide is expressed under regulatory control of endogenous non-human MHC II β er and regulatory ts.
3. The animal of claim 1, wherein a non-human portion of the chimeric human/nonhuman MHC II polypeptide comprises embrane and cytoplasmic domains of an nous non-human MHC II polypeptide and/or a non-human portion of the chimeric human/non-human MHC II β polypeptide ses transmembrane and cytoplasmic domains of an endogenous non-human MHC II β polypeptide.
4. The animal of claim 1, wherein the human portion of the chimeric human/non-human MHC II polypeptide is encoded by a HLA class II gene selected from the group consisting of any α chain gene of HLA-DR, HLA-DQ, and HLA-DP and/or the human portion of the chimeric human/non-human MHC II β polypeptide is encoded by a human HLA class II gene selected from the group consisting of any β chain gene of HLA-DR, HLA-DQ, and HLA-DP.
5. The animal of claim 4, wherein the human portion of the chimeric human/non-human MHC II polypeptide is encoded by a human HLA-DR4 α chain gene and/or the human portion of the ic human/non-human MHC II β polypeptide is encoded by a human HLADR4 β chain gene.
6. The animal of claim 1, n the animal is a rodent.
7. The rodent of claim 6, wherein the rodent is a mouse.
8. A non-human animal according to any one of claims 1 to 7, n the non-human animal is a rodent comprising at an endogenous MHC II gene locus a first nucleotide ce encoding a chimeric human/rodent MHC II polypeptide and a second nucleotide sequence encoding a chimeric human/rodent MHC II polypeptide, wherein a human portion of the chimeric human/rodent MHC II polypeptide ses a human MHC II 2 domain and a human portion of the chimeric human/rodent MHC II polypeptide comprises a human MHC II 2 domain, and wherein the chimeric human/rodent MHC II and MHC II ptides form a functional MHC II complex on a surface of a cell of the rodent.
9. The rodent of claim 8, wherein the rodent is a mouse.
10. The mouse of claim 9, wherein mouse portions of the chimeric MHC II and polypeptides are encoded by a mouse H-2E gene.
11. The rodent of claim 8, wherein the rodent does not express functional endogenous MHC II polypeptides from their endogenous rodent MHC II loci.
12. A method of modifying an MHC II locus of a mouse to express a chimeric human/mouse MHC II complex comprising replacing at the endogenous mouse MHC II α locus a nucleotide sequence encoding a mouse MHC II α protein with a first nucleotide sequence encoding a chimeric human/mouse MHC II α protein and/or at the endogenous mouse MHC II β locus a nucleotide sequence encoding a mouse MHC II β protein with a second nucleotide ce encoding a chimeric human/mouse MHC II β protein, wherein a chimeric human/mouse MHC II α protein comprises an α2 domain of a human MHC II polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II polypeptide and the chimeric human/mouse MHC II β protein comprises a β2 domain of a human MHC II β polypeptide and embrane and cytoplasmic domains of a mouse MHC II β polypeptide.
13. The method of claim 12, wherein a human portion of the chimeric MHC II complex is encoded by a human HLA class II chain gene ed from the group consisting of any chain gene of HLA-DR, HLA-DQ, and HLA-DP and/or by a human HLA class II β chain gene selected from the group ting of any β chain gene of HLA-DR, , and HLA-DP.
14. The method of claim 12, wherein a mouse portion of the chimeric MHC II complex is encoded by a mouse H-2E gene and/or d by a mouse H-2E β gene, and a human portion of the chimeric MHC II complex is encoded by a human HLA-DR4 gene and/or encoded by a human HLA-DR4 β gene.
15. The method of claim 12, wherein the replacement is made in a single ES cell, and the single ES cell is introduced into a mouse embryo to make a mouse.
16. The non-human animal of claim 1, the rodent of claim 6, or the mouse of claim 7, wherein the extracellular domain of the α polypeptide further comprises a human α1 domain d by a human HLA-DR gene.
17. The non-human animal of claim 1, the rodent of claim 6, or the mouse of claim 7, wherein the extracellular domain of the β ptide further comprises a human β1 domain encoded by a human HLA-DR β gene.
18. The non-human animal according to claim 1, or the method according to claim 12, substantially as herein described with reference to any of the Examples and/or
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ717130A NZ717130B2 (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552584P | 2011-10-28 | 2011-10-28 | |
US61/552,584 | 2011-10-28 | ||
PCT/US2012/062029 WO2013063340A1 (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623146A NZ623146A (en) | 2016-06-24 |
NZ623146B2 true NZ623146B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021200438B2 (en) | Genetically Modified Major Histocompatibility Complex Mice | |
US9700025B2 (en) | Genetically modified major histocompatibility complex animals | |
AU2014249148B2 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
RU2797549C2 (en) | Genetically modified mice expressing chimeric molecules of the major histocompatibility complex | |
NZ623146B2 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
NZ717130B2 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |